CytomX Therapeutics Inc (CTMX) reports encouraging results from its Varseta-M study, with plans for a pivotal trial and expansion into new tumor types.

Albany native Tyleia Harrell is a colon cancer survivor advocating for early screening and lifestyle changes to reduce cancer risk.

Company shares spiked more than 60% after the therapy surpassed Wall Street benchmarks in Phase 1 testing against late-line colorectal tumors.

CytomX Therapeutics Inc. CTMX shares are up during Monday’s premarket session as the company announced positive Phase 1 ...

Varseta-M Phase I CRC data, response rates, safety and registrational trial plans for 2027—read key insights now.

Under the collab, Walgreens customers will be able to access tools and resources to better understand their colorectal cancer screening options.

Shares of CytomX Therapeutics surged after the company reported positive data from an expanded Phase 1 trial of a colorectal cancer treatment, despite swinging to a loss in 2025. Shares were up 60% to ...

Colorectal cancer isn’t exclusive to the elderly. New studies from the American Cancer Society indicate rates of are moving in two different directions. The disease continues to decline in older ...

Women are more likely to survive cancer than men but face a higher risk of serious and adverse side effects from treatment, according to a landmark international study from Adelaide University.

Colorectal cancer, or cancer of the bowel or rectum, has long been associated with older adults. However, in recent years, cases among people under 50 have surged.

Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W -- Estimated progression free survival of ...